Sodium Cromoglicate 2%
Brand names: Opticrom, Catacrom, Hay-Crom
Sodium cromoglicate 2% eye drops are a topical mast-cell stabiliser used to prevent and relieve the symptoms of allergic conjunctivitis, including seasonal (hay fever) and perennial allergic eye disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It stabilises sensitised conjunctival mast cells and inhibits their degranulation, reducing the release of histamine and other inflammatory mediators that cause itching, redness and watering.
Prescribing in practice
- It works prophylactically and takes regular continued use over several days to reach full effect, so it is unsuitable as a single-dose treatment for an acute flare and should be used consistently throughout the allergy season.
- It treats allergy, not infection, so a painful red eye with discharge or reduced vision needs reassessment.
- Preserved formulations are incompatible with soft contact lens wear during instillation, though preservative-free options exist.
Monitoring
No laboratory monitoring is required; review symptom control and adherence to regular dosing.
Counselling the patient
- Use the drops regularly every day, ideally starting before the season, rather than only when symptoms appear.
- Allow several days of continuous use before judging how well it works.
- Remove soft contact lenses before instilling preserved drops.
Evidence & guidelines
Sodium cromoglicate is a long-established, well-tolerated prophylactic treatment for allergic conjunctivitis, available over the counter and supported by the SPC and allergy guidance.
Reference: NICE CKS (Allergic Conjunctivitis 2022); SPC Opticrom; SIGN 141 (Allergic Rhinitis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme